Abstracts tagged "outcomes and polymyalgia rheumatica"

Abstract Number: 1191 • 2016 ACR/ARHP Annual Meeting
Retinal Vessel Morphometry Associations with Polymyalgia Rheumatica; Findings from the European Prospective Investigation of Cancer (EPIC) in Norfolk
Max Yates¹, Shabina Hayat², Robert N. Luben³, Roshan Welikala⁴, Alicja Rudnicka⁵, Christopher Owen⁵, Sarah Barman⁴, Eoin O'Sullivan⁶, Sarah Mackie⁷, Richard Watts¹, Paul Foster⁸, Kay-Tee Khaw³, Nick Wareham³ and Alex J Macgregor⁹, ¹Norwich Medical School, University of East Anglia, Norwich, United Kingdom, ²Strangeways Research Laboratory, University of Cambridge, Cambridge, United Kingdom, ³Department of Public Health and Primary Care, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom, ⁴Faculty of Science, Engineering and Computing, University of Kingston, London, United Kingdom, ⁵Population Health Research Institute, St George's University of London, London, United Kingdom, ⁶Ophthalmology, Kings College Hospital, London, United Kingdom, ⁷NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, University of Leeds, Leeds, United Kingdom, ⁸Division of Epidemiology and Genetics, University College London, London, United Kingdom, ⁹Rheumatology, Norfolk and Norwich University Hospital, Norwich, United Kingdom
Background/Purpose: Increasing evidence suggests that characteristic changes in retinal vessel morphometry are biomarkers for vascular health. Polymyalgia Rheumatica (PMR) has been associated with increased risk…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].